



## Cerevel Therapeutics to Host Inaugural Virtual R&D Event

December 14, 2020

*Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs*

*Live webcast scheduled for Thursday, January 28 from 9:00 to 11:00 a.m. EST*

CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- [Cerevel Therapeutics](#) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host the first in a series of virtual R&D events on Thursday, January 28 from 9:00 to 11:00 a.m. EST. Hosted as a live webcast, Cerevel will lead an in-depth discussion of CVL-865, its Phase 2 GABA positive allosteric modulator (GABA PAM) as well as provide an overview of leading preclinical / early clinical assets. Subsequent R&D events dedicated to additional portfolio programs will be announced at a future time.

CVL-865 is currently being studied in two clinical trials, including the Phase 2 [REALIZE](#) trial evaluating the compound as an adjunctive therapy in adults with drug-resistant focal onset seizures, and a Phase 1 proof-of-principle trial for acute anxiety in healthy volunteers. Data from the REALIZE trial are expected in the second half of 2022 and data from the Phase 1 trial for acute anxiety are expected in the second half of 2021. This event is intended to provide a detailed look at the science behind the current clinical program, with time for questions.

The live webcast can be accessed on the investor relations section of the Cerevel Therapeutics website [here](#). A replay will be available in the same section of the company's website for approximately 90 days.

### About CVL-865

CVL-865 is a subtype selective positive allosteric modulator (PAM) that targets GABA<sub>A</sub> receptors containing  $\alpha 2/3/5$  subunits. It is structurally differentiated from classical benzodiazepines and minimizes activity at  $\alpha 1$ -containing receptors, which is believed to help mitigate many of the adverse events associated with benzodiazepines. To date, CVL-865 has been evaluated in 289 patients and healthy volunteers across nine clinical trials, with results showing it to be generally well-tolerated. A Phase 2 single-dose trial demonstrated robust anticonvulsant activity in patients with photosensitive epilepsy (a type of epilepsy in which seizures are triggered by flashing lights), with six of seven patients treated with CVL-865 experiencing complete suppression of intermittent photic stimulation (IPS), a characteristic epileptiform discharge shown on electroencephalograms (EEGs). For more information about the Phase 2 clinical trial, please visit <https://realizestudy.com>.

### About Cerevel Therapeutics

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit [www.cerevel.com](http://www.cerevel.com).

### Special Note Regarding Forward-Looking Statements

*This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of our product candidates, the format and timing of our product development activities and clinical trials, including the expected timing of data announcements. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: that clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading "Risk Factors" in our definitive proxy statement/prospectus filed with the SEC on October 7, 2020. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.*

### Media Contact:

Rachel Eides  
W2O pure  
[reides@purecommunications.com](mailto:reides@purecommunications.com)

**Investor Contact:**

Matthew Calistri  
Cerevel Therapeutics  
[matthew.calistri@cerevel.com](mailto:matthew.calistri@cerevel.com)